Purchase Order 75N91018P00316
Award Date 5/19/18
Potential Completion Date 5/18/23
Potential Value $300K
Federal Agency
Awardee
Ultimate Awardee
Not listed Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Bethesda, MD 20892, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This firm-fixed-price purchase order was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) under the U.S. Department of Health and Human Services (HHS), to Illumina, Inc. for preventive maintenance, emergency service, and support for a government-owned Illumina NextSeq 2000 sequencing system. The $235,228 contract has a final performance date of September 22, 2025 and was terminated for convenience. Illumina is a for-profit biotechnology company that...
- This is a $145,853.00 firm fixed price purchase order awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute to Illumina, Inc. The contract is for a maintenance agreement for scientific equipment, specifically Illumina's NextSeq, NovaSeq, MiSeq, and iSeq sequencing systems and related reagents and consumables. Illumina is a for-profit manufacturer that has provided a range of genomic sequencing and analysis products and services...
- This federal contract award, valued at $81,706.00, was granted to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies, by the National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH) under the Department of Health and Human Services (HHS). The contract is for preventive maintenance, emergency service, and support for a government-owned Illumina NextSeq 550 sequencer in support of the NCI's Center for Cancer Research...
- This is a $114,198.14 firm fixed price purchase order awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Illumina, Inc. for their NextSeq 550 comprehensive service plan. The contract is not set aside and has an ultimate completion date of July 31, 2024. Illumina is a manufacturer of sequencing and array-based solutions for genetic and genomic analysis, and has previously received prime federal contracts and subcontracts from agencies...
- The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute awarded a firm fixed price delivery order contract valued at $168,705.00 to Illumina, Inc., a for-profit manufacturer of genomic sequencing and analysis products. The contract is for the provision of biological kits, with a completion date of June 22, 2024. Illumina has previously been awarded prime contracts and subcontracts across various federal agencies, including the NIH,...
- This is a firm fixed price purchase order awarded by the National Cancer Institute, a civilian agency within the U.S. Department of Health and Human Services, to Illumina, Inc., a for-profit manufacturer of genomic sequencing and analysis equipment. The contract provides for an equipment maintenance agreement on Illumina sequencing systems, such as NextSeq, NovaSeq, MiSeq, and iSeq models, with a ceiling value of $16,198.00 and a performance period ending on December 4, 2025. The contract does...
- The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute awarded a $228,009.60 firm fixed-price delivery order contract to Illumina, Inc., a for-profit manufacturer of genomic sequencing instruments and reagents. The contract has a completion date of March 19, 2024 and is for the provision of biological kits. Illumina has a history of providing sequencing systems, consumables, and bioinformatics products to federal agencies like the NIH,...
- The National Cancer Institute awarded a $93,351.36 firm fixed-price purchase order to Illumina, Inc. on April 1, 2026, for a two-year maintenance agreement covering two NextSeq 2000 sequencers located at the agency's Bethesda, Maryland facility. The contract, which extends through March 31, 2027, represents a standard service and support engagement for Illumina's widely-deployed genetic sequencing instruments across the federal research enterprise. No set-aside designation was applied to this...
- The National Cancer Institute (NCI) awarded a $116,652 firm fixed-price purchase order to Illumina, Inc. for preventative maintenance services on an Illumina NextSeq 550 sequencer. The contract was awarded without a set-aside and covers an initial base period from 8/21/2020 to 8/20/2021, with a total performance period through 5/7/2025. Illumina is the original equipment manufacturer (OEM) and the only known provider of these specialized maintenance services. The contract supports the NCI's...
- The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a firm fixed price purchase order contract to Illumina, Inc. for maintenance services on the agency's Illumina MiSeq and NextSeq gene sequencing instruments. The contract has a potential value of $240,423.72 and covers a 12-month base period from May 13, 2019 to May 12, 2020, with four 12-month option periods. The contract provides for preventive maintenance inspections, replacement parts,...